Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Average PT from Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $41.20.

Several equities analysts recently issued reports on BCAX shares. HC Wainwright boosted their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Finally, RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $13.09 on Friday. The stock has a fifty day moving average of $14.83. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BCAX. RA Capital Management L.P. bought a new position in shares of Bicara Therapeutics during the third quarter valued at $177,169,000. Red Tree Management LLC purchased a new stake in Bicara Therapeutics during the 4th quarter valued at about $55,230,000. FMR LLC bought a new stake in Bicara Therapeutics during the 3rd quarter valued at about $57,913,000. Adage Capital Partners GP L.L.C. raised its holdings in Bicara Therapeutics by 171.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock worth $37,893,000 after buying an additional 1,375,265 shares during the last quarter. Finally, Braidwell LP lifted its stake in shares of Bicara Therapeutics by 20.7% in the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock worth $34,851,000 after buying an additional 343,059 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.